VIM and hepatocellular carcinoma: In particular, ARHGAP5‐AS1 could interrupt interactions between CSDE1 and TRIM28, stabilise oncoprotein CSDE1, boost translation of VIM and RAC1 mRNAs, stimulate the ERK signalling and, thus, accelerate HCC progression.